Beneficial Effects of Moxonidine on Cerebral Vasospasm After Experimental Subarachnoid Hemorrhage
Yükleniyor...
Tarih
2014
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
AMAÇ: Çalışma I1-imidazolin bölgeleri için selektif bir ligand olan merkezi etkili antihipertansif ajan moksonidinin bir tavşan serebral vazospazm modelinde etkinliğini incelemek üzere tasarlanmıştır. YÖNTEM ve GEREÇlER: Yirmi dört beyaz, 2500-3200 gr. ağırlığında erkek, Yeni Zelanda tavşanı rasgele olarak üç gruba bölünmüştür grup 1 kontrol grubu, grup 2sadece subaraknoid kanama (SAK) grubu ve grup 3SAK moksonidin (tedavi) grubu. Tüm tavşanlarda SAK indüksiyonu öncesinde (Gün0, bazal anj iyografi) ve 72 saat sonrasında serebral anj iyografi yapılmıştır. SAK indüksiyonundan sonra tedavi grubunda intraperitoneal moksonidin (0,5 mg/kg) tedavisi başlatılmış ve günde bir kez olmak üzere 72 saat devam ettirilmiştir. BULGULAR: Gruplar arasında baziller arterin anj iyografik luminal çapı açısından istatistiksel olarak önemli bir fark bulunmamıştır (p0,005). SAK sonrasında takip anj iyografik baziller arter luminal çapı sadece SAK grubu ile karşılaştırıldığında tedavi grubunda istatistiksel olarak anlamlı şekilde değişiklik göstermiştir (p0,001). Patoloj ik olarak incelenen baziller arter lümeni alanı bu iki grup arasında istatistiksel açıdan anlamlı fark göstermiştir (p0,005). SONUÇ: Merkezi etkili bir antihipertansif ajan olarak moksonidin tedavisi anj iyografik çapı ve patoloj ide lümen alanını artırıp müsküler duvar kalınlığını azaltarak vazospazm tedavisinde çok faydalı bulunmuştur.
AIM: This study was designed to examine the efficacy of moxonidine, a centrally acting antihypertensive agent that is a selective ligand for I1-imidazoline sites, in a rabbit cerebral vasospasm model. MATERIAL and METHODS: Twenty-four white, male New-Zealand rabbits weighing 2500-3200 gr. were randomly allocated into three groups as group 1 control group, group 2subarachnoid hemorrhage (SAH) alone group, and group 3SAH moxonidine (treatment) group. Cerebral angiography was performed to all rabbits before (Day0, basal angiography) and 72 hours after the induction of SAH. Intraperitoneal moxonidine (0.5 mg/kg) treatment was started after the induction of SAH and continued once a day for 72 hours in the treatment group. RESULTS: No statistically significant difference was determined in basal angiographic luminal diameter of the basilar artery between groups (p<0.005). After SAH, the follow-up angiographic basilar artery luminal diameter significantly changed in treatment group when compared with the SAH alone group (p>0.001). The pathologically examined basilar artery luminal area was different between these groups (p>0.005). CONCLUSION: Moxonidine treatment as a centrally acting antihypertensive agent was found to be very beneficial in the treatment of vasospasm by increasing the angiographic diameter and the pathologic luminal area and reducing muscular wall thickness.
AIM: This study was designed to examine the efficacy of moxonidine, a centrally acting antihypertensive agent that is a selective ligand for I1-imidazoline sites, in a rabbit cerebral vasospasm model. MATERIAL and METHODS: Twenty-four white, male New-Zealand rabbits weighing 2500-3200 gr. were randomly allocated into three groups as group 1 control group, group 2subarachnoid hemorrhage (SAH) alone group, and group 3SAH moxonidine (treatment) group. Cerebral angiography was performed to all rabbits before (Day0, basal angiography) and 72 hours after the induction of SAH. Intraperitoneal moxonidine (0.5 mg/kg) treatment was started after the induction of SAH and continued once a day for 72 hours in the treatment group. RESULTS: No statistically significant difference was determined in basal angiographic luminal diameter of the basilar artery between groups (p<0.005). After SAH, the follow-up angiographic basilar artery luminal diameter significantly changed in treatment group when compared with the SAH alone group (p>0.001). The pathologically examined basilar artery luminal area was different between these groups (p>0.005). CONCLUSION: Moxonidine treatment as a centrally acting antihypertensive agent was found to be very beneficial in the treatment of vasospasm by increasing the angiographic diameter and the pathologic luminal area and reducing muscular wall thickness.
Açıklama
Anahtar Kelimeler
Cerrahi, Subarachnoid Hemorrhage, Cerebral Vasospasm, Experimental, Moxonidine, Rabbit, Subaraknoid Kanama, Serebral Vazospazm, Deneysel, Moksonidin, Tavşan
Kaynak
Turkish Neurosurgery
WoS Q Değeri
Q4
Scopus Q Değeri
Q3
Cilt
24
Sayı
6
Künye
Ilık, K., Kocaoğullar, Y., Koç, O., Esen, H. (2014). Beneficial effects of moxonidine on cerebral vasospasm after experimental subarachnoid hemorrhage. Turkish Neurosurgery, 24, 6, 873-879.
